Atrium Therapeutics dosed its first patient in the Corventis Phase 1/2 trial on October 27, raising a question that matters for the rare cardiac disease field: can a single small interfering RNA therapy normalize a gene defect in the heart that current medicine can only manage symptom by symptom? ATR-1072, Atrium’s lead candidate, targets PRKAG2 syndrome, an autosomal dominant glycogen storage disease of the heart that causes left ventricular hypertrophy, conduction abnormalities, and ventricular pre-excitation. Current standard-of-care options have generally focused on symptomatic management, and ATR-1072 is designed to target the underlying genetic cause.
The Corventis study is an a Phase 1/2 clinical trial for adults with genetically confirmed PRKAG2 syndrome. The design reflects the program’s ambition: it. That matters because PRKAG2 syndrome , a narrow population that makes large parallel-arm trials impractical., which is the biological rationale for a therapy designed around infrequent dosing.
The siRNA mechanism is what separates this program from device-based interventions like pacemakers or ablation procedures, which manage the electrical consequences of the disease without touching its cause. ATR-1072 is designed to silence the mutant PRKAG2 mRNA in cardiac tissue, aiming to reduce the glycogen accumulation that drives structural and electrical deterioration. Whether that translates in humans is what Corventis is built to answer. The trial’s small enrollment ceiling means the will carry significant weight per patient, and a clean safety and pharmacodynamics readout would move the program quickly toward a pivotal decision.
The marker to watch when interim data arrive is whether ATR-1072 produces measurable reductions in cardiac PRKAG2 mRNA in humans at doses consistent with the preclinical signal, because that pharmacodynamic bridge is the threshold the program needs before dose selection for any later-stage study.
Source link: https://www.sec.gov/Archives/edgar/data/2093101/000119312526432949/d134020d8k.htm
ATR-1072: the facts in one place
- Also written: ATR 1072
- Sponsor: Atrium Therapeutics, Inc.
- Mechanism: antibody oligonucleotide conjugate (AOC) that silences mutant PRKAG2 mRNA to normalize AMPK activity and reduce pathogenic glycogen accumulation
- Indication studied: PRKAG2 syndrome, a rare inherited cardiomyopathy
- Phase: Phase 1/2
- Enrollment: 37
- Primary endpoint: incidence of treatment-emergent adverse events
- Registry identifier: NCT07738107
- Current status: Active; first patient dosed October 27, 2026 in the open-label Corventis trial.
- FDA IND clearance: July 14, 2026
- Health Canada No Objection Letter issued: not precisely dated in summary
- First patient dosed (Corventis trial): October 27, 2026
- ClinicalTrials.gov last updated: September 18, 2026
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
